A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

This long-term study evaluates the safety and ongoing effectiveness of SHR-1703 — a new biologic injection — for people with eosinophilic asthma, a type of asthma driven by high levels of eosinophils (a type of immune cell that causes airway inflammation and makes breathing difficult). **You may be eligible if...** - You are 18 years old or older and weigh at least 40 kg - You have been diagnosed with asthma for at least 1 year - Your asthma is currently treated with medium or high-dose inhaled corticosteroids plus another controller medication - Your eosinophil levels and asthma severity meet the study's thresholds **You may NOT be eligible if...** - You have another serious lung disease (such as COPD) - You have had a severe asthma attack requiring hospitalization recently - You are on other biologic medications for asthma - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.